Form 4: Madrigal Director Exercises Options, Sells Shares

Madrigal Pharmaceuticals Director Paul A. Friedman exercised stock options and subsequently sold 280 shares of common stock under a pre-arranged trading plan.

Summary

• Director Paul A. Friedman exercised 280 stock options for Madrigal Pharmaceuticals common stock at an exercise price of $15.80 per share.
• Concurrently, Mr. Friedman sold 280 shares of common stock at a weighted average price of $551.2414 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 10, 2025.
• Following these transactions, Mr. Friedman directly owns 187,164 shares of common stock.
• Additionally, 655,540 shares are indirectly owned by SQN LLC, where Mr. Friedman and his spouse are managing members.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be seen negatively, the transaction was pre-planned under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling based on new negative information. It represents a routine liquidity event for the director.

Positives

• The exercise of options indicates the director realized value from previously granted equity.
• The sale was conducted under a Rule 10b5-1 trading plan, which suggests a pre-planned transaction rather than a reaction to recent events.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake.

Future Outlook

NA

Industry Context

This Form 4 filing reflects routine insider trading activity for a director at a pharmaceutical company. Such transactions, especially when conducted under a Rule 10b5-1 plan, are common for executives managing their personal portfolios and do not necessarily indicate a change in the company's fundamental outlook or broader industry trends.

Related Party Transactions

• Paul A. Friedman and his spouse are managing members of SQN, LLC, which indirectly owns 655,540 shares of Madrigal Pharmaceuticals common stock. Mr. Friedman disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may note the director's reduction in direct equity holdings, though the pre-planned nature of the sale under Rule 10b5-1 suggests it is a personal financial management decision rather than a reflection of company performance.

Key Dates

Recommendation

The filing details a routine insider transaction where a director exercised options and sold shares under a pre-arranged 10b5-1 trading plan. This type of transaction is typically for personal financial management and does not inherently signal a change in the company's fundamental prospects. Therefore, it does not provide a strong basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Madrigal Pharmaceuticals, MDGL, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Paul A. Friedman, Rule 10b5-1